MERTK and neoplasm: Consistent with previous reports of MERTK blockade enhancing anti-tumor response (Cook et al., 2013; Davra et al., 2021; Huelse et al., 2020; Lee-Sherick et al., 2020; Lin et al., 2022; Lindsay et al., 2021; Sekar et al., 2022; Su et al., 2020; Wu et al., 2018; Zhou et al., 2020), 93.75% of Mertk-/-V1 mice remained tumor free compared to 0% of B6 WT control mice (Figure 5B).